Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Get Free Report) saw strong trading volume on Monday . Approximately 60,917 shares changed hands during mid-day trading, a decline of 3% from the previous session’s volume of 62,664 shares.The stock last traded at $39.4320 and had previously closed at $38.40.
Analyst Ratings Changes
A number of brokerages recently issued reports on NBTX. TD Cowen reissued a “buy” rating on shares of Nanobiotix in a research note on Thursday, March 12th. Guggenheim upped their price objective on Nanobiotix from $26.00 to $36.00 and gave the company a “buy” rating in a research report on Thursday, April 2nd. UBS Group increased their target price on Nanobiotix from $3.50 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, May 1st. HC Wainwright reiterated a “buy” rating on shares of Nanobiotix in a research report on Monday, May 18th. Finally, Leerink Partners boosted their target price on shares of Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a research note on Thursday, June 4th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Nanobiotix has a consensus rating of “Moderate Buy” and a consensus price target of $37.33.
Check Out Our Latest Stock Report on NBTX
Nanobiotix Stock Performance
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the company. Royal Bank of Canada lifted its holdings in shares of Nanobiotix by 2,000.0% in the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after buying an additional 2,500 shares during the period. Marshall Wace LLP bought a new stake in shares of Nanobiotix in the fourth quarter valued at about $220,000. Finally, Millennium Management LLC bought a new stake in shares of Nanobiotix in the fourth quarter valued at about $390,000. 38.81% of the stock is currently owned by hedge funds and other institutional investors.
About Nanobiotix
Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.
Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.
Further Reading
- Five stocks we like better than Nanobiotix
- This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street
- AI Is Selling Off, But These 5 Stocks Could Benefit Next
- These 3 Stocks Offer Investors Exposure to the Functional Beverage Boom
- Alcoa’s $4.1 Billion South32 Deal: Opportunity Behind the 9% Drop
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
